DNLI

Denali Therapeutics Inc.

19.84 USD
-0.37 (-1.83%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Denali Therapeutics Inc. stock is up 18.73% since 30 days ago. The next earnings date is May 6, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 16.67% of the previous 6 March’s closed higher than February. In the last 4 Unusual Options Trades, there were 3 CALLs, 1 PUT. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
08 Jan 20:24 15 Mar, 2024 20.00 CALL 100 322
27 Feb 15:38 21 Jun, 2024 25.00 CALL 545 356
27 Feb 17:19 21 Jun, 2024 20.00 CALL 125 142
27 Feb 20:35 21 Jun, 2024 25.00 PUT 89 0

About Denali Therapeutics Inc.

Denali Therapeutics Inc. discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate product candidate. BIIB122/DNL151, a small molecule inhibitor, is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease.